Licensing & Partnerships


MTORX Technology has potential broad utility because of its ability to regulate autophagy and inflammatory signaling without the antiproliferative or immunosuppressant side effects of traditional autophagy inducers. This utility has led to a variety of other potential indications at various stages of development. MTORX Technology showed positive results in these indications but we are currently prioritizing our rare disease pipeline. If you are interested in potentially out licensing one of these specific indications, please contact BioMendics to discuss availability and potential collaboration.

An Investigational New Drug application is currently in effect with the U.S. Food and
Drug Administration for BM-3103.
Wound Healing
Chronic Wounds (Scarring)
Burns (Infected)


BioMendics partners with leading academic institutions and university researchers to advance its science and identify new drug candidates.


Stanford University arrow-uparrow-down

Albert Chiou, MD, PhD Principal Investigator: Dr. Albert Chiou is a Clinical Associate Professor of Dermatology. He earned his Bachelor of Science and completed his dermatology residency at Stanford University and completed an MPhil in Chemistry, as a Gates Cambridge Scholar. He received his medical degree from Harvard Medical School, where he also completed a joint business degree. His clinical focus includes epidermolysis bullosa, atopic dermatitis, acne, psoriasis, skin cancer, and dermatologic surgery.

Jean Tang, MD, PhD Co-PI: Dr. Jean Tang is a Professor of Dermatology at Stanford, and her research focuses on genetic skin diseases such as epidermolysis bullosa (EB) and basal cell nevus syndrome. Dr. Tang has led or co-led the conduct and completion of 6 investigator initiated clinical trials in basal cell carcinoma and EB. She received her MD/PhD from Stanford (Biophysics), completed her dermatology residency at Stanford, a 3-year post-doc at the University of California San Francisco in genetics, along with formal coursework in biostatistics, epidemiology, and clinical trial design in the KL2 CTSI program.

Joyce Teng, MD, PhD Co-PI: Dr. Joyce Teng is a professor in dermatology at Stanford University. She is affiliated with the Lucile Salter Packard Children’s Hospital (LPCH) at Stanford and Stanford Hospital and Clinics (SHC). She received her degree from Vanderbilt University School of Medicine and has been in practice for 12+ years. She sees children with EB and other rare genetic disorders. Her research interests are drug discovery and novel therapy for skin disorders.


University of Miami arrow-uparrow-down

Robert Kirsner, MD Dr. Robert Kirsner is the Chairman and Tenured Professor in the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine and holds the Harvey Blank Chair. He is the Chief of Dermatology at the University of Miami Hospital. As the director for the Wound Center, Dr. Kirsner conducts both company and physician sponsored clinical research. Dr. Kirsner’s specialties include wound healing, leg ulcers, skin cancer, medical dermatology, and cutaneous surgery. He is on the editorial boards for multiple journals in Dermatology and Wound Healing and has over 500 peer-reviewed publications.

Stephen Davis, PhD Dr. Stephen Davis is a research professor who has over 30 years’ experience using various wound healing and infection models in swine. He worked with William H. Eaglstein, MD, and Patricia M. Mertz who pioneered the first animal porcine model in the mid 1970s. Using these models, Dr. Davis and his team have expanded their current knowledge of moist wound healing, evaluated the in-vivo effects of numerous agents on bacterial proliferation and bacterial biofilms as well as helped to determine mechanisms and efficacy of various products/technologies that are on the market today e.g., DuoDerm dressing, Kerlix A.M.D., Liquid Bandage, Iodoflex and Procellera.


University of California Davis arrow-uparrow-down

Min Zhao, MD, PhD Dr. Min Zhao is a professor of dermatology at the UC Davis School of Medicine. He is also an honorary professor at the University of Aberdeen, Cardiff University and a guest professor at the 3rd Military Medical University, China. Dr. Zhao graduated from the 3rd Military Medical University in Chongqing, China. After completion of PhD training under the supervision of Professor Zhengguo Wang, he joined Professor Geoff Burnstock at University College, London. He then moved to the University of Aberdeen as a research fellow to work with Professors Colin McCaig and John Forrester. In 2007, he moved to UC Davis and is currently a Professor of Dermatology and Ophthalmology.

His research is aimed toward improving wound healing and regeneration of damaged or diseased tissues. His current work focuses on:

  • The role of naturally occurring electric fields or electric currents in wound healing and tissue regeneration.
  • Development of therapies to electrically stimulate and direct wound healing and tissue regeneration.
  • Targeting stem cell migration.

Brian Reid, PhD Dr. Brian Reid graduated from the University of Aberdeen, Scotland with a BSc in Microbiology. He then went on to complete a PhD studying electrotaxis of zoosporic fungi. Following his PhD, he worked on vesicle recycling in retinal bipolar cells at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England and later worked on the specificity of nerve-muscle interaction with Dr. Guy Bewick. He joined the laboratory of Dr. Min Zhao in 2001. Dr. Reid’s projects include: Electric fields and wound healing in human and rat cornea; Role of electric fields and ion flux in Xenopus frog tadpole tail regeneration; Wound healing in primate airway epithelium; Electrical activity in brain after traumatic injury; Feather bud development.